Matter Bio Raises $7M to Advance Aging Research and Clinical Trials

Matter Bio's Seed Funding

Key Highlights:

• Seed Funding: Matter Bio, a biotech company focused on preserving genome integrity and extending human lifespan, raised $7 million in seed funding.
• Investors: Lifespan Vision Ventures led the round, with participation from quadraScope Ventures and others.
• Research and Clinical Trials: The funding will support further research into the information theory of aging, filing an IND, and initiating a Phase 1/2a clinical trial in solid cancer.

Matter Bio's Target Market

• Target Market: Individuals and organizations interested in longevity biotechnology and addressing the complexities of aging.
• Biotech and Pharmaceutical Companies: Potential partners for collaborative research and development in the field of genome integrity and aging.
• Healthcare Providers and Researchers: Professionals focused on understanding and addressing the challenges of aging and genome instability.

What Matter Bio Needs to Buy

• Research and Laboratory Equipment: Investments in advanced laboratory equipment and technologies to support ongoing research and development.
• Clinical Trial Support Services: Collaborations with contract research organizations (CROs) and clinical trial service providers for conducting Phase 1/2a clinical trials.
• Partnerships in Biotech and Pharma: Collaborations with biotech and pharmaceutical companies for joint research and development efforts.